Current Research Studies

Post-trial Access Program: Idursulfase-IT (HGT-2310) in Conjunction with Intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cognitive Impairment

TAK609 PTA

Phase: N/A
Clinicaltrials.gov ID: NCT05795361

What is the goal of the study?

This is a post trial access program to continue to allow continued study drug (intrathecal idursulfase) access for our Hunter Syndrome patients that were previously enrolled in the HGTHIT046 trial.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Christina Lam
Study Team Member: Hayden Vreugdenhil, [email protected]